|
- Venetoclax - Wikipedia
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML) [7][8]
- Venetoclax: Uses, Dosage, Side Effects, Warnings - Drugs. com
Venetoclax (brand name Venclexta) may be used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults, or newly diagnosed acute myeloid leukemia (AML) in those aged 75 years or older, or with other conditions that prevent intensive chemotherapy
- VENCLEXTA® (venetoclax tablets): CLL SLL and AML Treatment
Discover VENCLEXTA® (venetoclax tablets): An oral therapy to help you fight certain blood cancers See full Prescribing and Safety information
- Venetoclax (oral route) - Mayo Clinic
Venetoclax is used alone or together with other medicines (eg, rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, in patients who have received at least one previous treatment
- Venetoclax - NCI - National Cancer Institute
Venetoclax is approved to treat: Acute myeloid leukemia that is newly diagnosed It is used in adults aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy It is given with either azacitidine, decitabine, or low-dose cytarabine
- Venclexta (Venetoclax): Uses in Cancer, Side Effects, Dosages . . .
Venetoclax is a key treatment for chronic lymphocytic leukemia (CLL), particularly for relapsed or refractory cases It is often used in combination with rituximab or obinutuzumab
- Venetoclax Tablets: Uses Side Effects - Cleveland Clinic
VENETOCLAX (ven et oh klax) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing It is used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myelogenous leukemia
- Practical Management of the Venetoclax-Treated Patient in Chronic . . .
This article discusses the efficacy and safety of venetoclax administration and presents strategies specifically for the management of neutropenia and certain nonhematologic adverse events in patients receiving venetoclax for the treatment of AML and CLL
|
|
|